3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
2
Phase 2
2
Phase 1
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma
4
NSCLC
3
Lung Neoplasms
3
Neoplasm Metastasis
2
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Non-small Cell Carcinoma
1
Neoplasms
1
Neoplasm, Residual
1
NSCLC Patients With Brain Metastasis
1
Locally Advanced or Metastatic Non-squamous NSCLC
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Bronchial Neoplasms
1
Brain Neoplasms
1
Anticancer Treatment
1
Interventions
Leucovorin
22
Fluorouracil
22
Paclitaxel
21
Gemcitabine
21
Docetaxel
21
Capecitabine
21
Irinotecan
16
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
osimertinib
×
Clear all
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA